Genedata, a provider of advanced software solutions for biopharmaceutical R&D, has announced its Genedata Bioprocess platform has been integrated with MODDE, the Design of Experiment (DOE) software from Sartorius Stedim Data Analytics. The integration allows the MODDE (DOE) software to be plugged into the Genedata Bioprocess platform, which acts as a data backbone connecting all planning and actual experimental information from upstream, downstream, formulation, and analytical development units. This integration capability allows for consistent information exchange between the two systems, ensuring data integrity and streamlining the data transfer and analysis process.
'The bioprocess development market has clear needs for advanced data analytics delivered as an integrated and turn-key solution,' said Professor Dr Johan Trygg, head of advanced data analytics corporate research at Sartorius. 'With the integration of our MODDE software with the Genedata Bioprocess platform, we enable a higher degree of automation capability in the bioprocess development workflow. In addition, seamless access to all experimental data stored in Genedata Bioprocess, in combination with MODDE software capabilities for modelling, optimisation, and risk evaluation, promote efficient implementation of a Quality by Design (QbD) strategy.'
The joint approach for enabling efficient QbD strategies in bioprocess development is empowered by combining experimental workflow management with the power of Design of Experiments (DOE) technology. With this new bi-directional integration, MODDE experimental design data can be seamlessly imported into the Genedata Bioprocess platform, where process parameters and experiment results are stored. This data, in turn, can be passed back into MODDE for optimisation studies and risk evaluation.
'Our collaboration with Sartorius Stedim Data Analytics enables fully integrated DOE-experimentation workflows and significantly simplifies our customer’s day-to-day operations, saves time, and lowers their R&D costs,' said Dr Othmar Pfannes, CEO of Genedata. 'In addition, the plug-and-play functionality enables a straightforward setup of a fully integrated platform, which minimises installation costs. We look forward to expanding our established Ready-to-Run program to other technologies to further streamline our customers’ bioprocess development operations.'
ESACT - European Society for Animal Cell Technology Editorial Note:
Genedata Bioprocess will be showcased in the ESACT presentation, “Industrializing Immuno-Oncology Therapeutic Discovery Platforms,” on Tuesday, May 7, 2019 at 12:20 pm.
